TY  - JOUR
AU  - McGuire, Darren K
AU  - Alexander, John H
AU  - Johansen, Odd Erik
AU  - Perkovic, Vlado
AU  - Rosenstock, Julio
AU  - Cooper, Mark E
AU  - Wanner, Christoph
AU  - Kahn, Steven E
AU  - Toto, Robert D
AU  - Zinman, Bernard
AU  - Baanstra, David
AU  - Pfarr, Egon
AU  - Schnaidt, Sven
AU  - Meinicke, Thomas
AU  - George, Jyothis T
AU  - von Eynatten, Maximilian
AU  - Marx, Nikolaus
AU  - CARMELINA Investigators
PY  - 2019
DO  - 10.1161/CIRCULATIONAHA.118.038352
UR  - https://hdl.handle.net/10668/26969
T2  - Circulation
AB  - Individuals with type 2 diabetes mellitus are at increased risk for heart failure (HF), particularly those with coexisting atherosclerotic cardiovascular disease and/or kidney disease. Some but not all dipeptidyl peptidase-4 inhibitors have been...
LA  - en
KW  - cardiovascular disease
KW  - chronic kidney diseases
KW  - heart failure
KW  - type 2 diabetes mellitus
KW  - Aged
KW  - Atherosclerosis
KW  - Biomarkers
KW  - Diabetes Mellitus, Type 2
KW  - Dipeptidyl-Peptidase IV Inhibitors
KW  - Double-Blind Method
KW  - Female
KW  - Glomerular Filtration Rate
KW  - Glycated Hemoglobin
KW  - Heart Failure
KW  - Humans
KW  - Kidney
KW  - Kidney Diseases
KW  - Linagliptin
KW  - Male
KW  - Middle Aged
KW  - Prevalence
KW  - Prospective Studies
KW  - Risk Assessment
KW  - Risk Factors
KW  - Time Factors
KW  - Treatment Outcome
TI  - Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
TY  - research article
VL  - 139
ER  -